Cargando…

Pharmacokinetic Properties of DNA Aptamers with Base Modifications

The addition of novel side chains at the 5-position of uracil is an effective means to increase chemical diversity of aptamers and hence the success rate for discovery of high-affinity ligands to protein targets. Such modifications also increase nuclease resistance, which is useful in a range of app...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Shashi, Drolet, Daniel W., Wolk, Steven K., Waugh, Sheela M., Rohloff, John C., Carter, Jeffery D., Mayfield, Wesley S., Otis, Matthew R., Fowler, Catherine R., Suzuki, Tomoki, Hirota, Masao, Ishikawa, Yuichi, Schneider, Daniel J., Janjic, Nebojsa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706628/
https://www.ncbi.nlm.nih.gov/pubmed/28961063
http://dx.doi.org/10.1089/nat.2017.0683
_version_ 1783282259896303616
author Gupta, Shashi
Drolet, Daniel W.
Wolk, Steven K.
Waugh, Sheela M.
Rohloff, John C.
Carter, Jeffery D.
Mayfield, Wesley S.
Otis, Matthew R.
Fowler, Catherine R.
Suzuki, Tomoki
Hirota, Masao
Ishikawa, Yuichi
Schneider, Daniel J.
Janjic, Nebojsa
author_facet Gupta, Shashi
Drolet, Daniel W.
Wolk, Steven K.
Waugh, Sheela M.
Rohloff, John C.
Carter, Jeffery D.
Mayfield, Wesley S.
Otis, Matthew R.
Fowler, Catherine R.
Suzuki, Tomoki
Hirota, Masao
Ishikawa, Yuichi
Schneider, Daniel J.
Janjic, Nebojsa
author_sort Gupta, Shashi
collection PubMed
description The addition of novel side chains at the 5-position of uracil is an effective means to increase chemical diversity of aptamers and hence the success rate for discovery of high-affinity ligands to protein targets. Such modifications also increase nuclease resistance, which is useful in a range of applications, especially for therapeutics. In this study, we assess the impact of these side chains on plasma pharmacokinetics of modified aptamers conjugated to a 40 kDa polyethylene glycol. We show that clearance from plasma depends on relative hydrophobicity: side chains with a negative cLogP (more hydrophilic) result in slower plasma clearance compared with side chains with a positive cLogP (more hydrophobic). We show that clearance increases with the number of side chains in sequences of ≥28 synthons, but this effect is dramatically diminished in shorter sequences. These results serve as a guide for the design of new therapeutic aptamers with diversity-enhancing side chains.
format Online
Article
Text
id pubmed-5706628
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Mary Ann Liebert, Inc.
record_format MEDLINE/PubMed
spelling pubmed-57066282017-12-01 Pharmacokinetic Properties of DNA Aptamers with Base Modifications Gupta, Shashi Drolet, Daniel W. Wolk, Steven K. Waugh, Sheela M. Rohloff, John C. Carter, Jeffery D. Mayfield, Wesley S. Otis, Matthew R. Fowler, Catherine R. Suzuki, Tomoki Hirota, Masao Ishikawa, Yuichi Schneider, Daniel J. Janjic, Nebojsa Nucleic Acid Ther Original Articles The addition of novel side chains at the 5-position of uracil is an effective means to increase chemical diversity of aptamers and hence the success rate for discovery of high-affinity ligands to protein targets. Such modifications also increase nuclease resistance, which is useful in a range of applications, especially for therapeutics. In this study, we assess the impact of these side chains on plasma pharmacokinetics of modified aptamers conjugated to a 40 kDa polyethylene glycol. We show that clearance from plasma depends on relative hydrophobicity: side chains with a negative cLogP (more hydrophilic) result in slower plasma clearance compared with side chains with a positive cLogP (more hydrophobic). We show that clearance increases with the number of side chains in sequences of ≥28 synthons, but this effect is dramatically diminished in shorter sequences. These results serve as a guide for the design of new therapeutic aptamers with diversity-enhancing side chains. Mary Ann Liebert, Inc. 2017-12-01 2017-12-01 /pmc/articles/PMC5706628/ /pubmed/28961063 http://dx.doi.org/10.1089/nat.2017.0683 Text en © Shashi Gupta et al. 2017; Published by Mary Ann Liebert, Inc. This article is available under the Creative Commons License CC-BY-NC (http://creativecommons.org/licenses/by-nc/4.0). This license permits non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited. Permission only needs to be obtained for commercial use and can be done via RightsLink.
spellingShingle Original Articles
Gupta, Shashi
Drolet, Daniel W.
Wolk, Steven K.
Waugh, Sheela M.
Rohloff, John C.
Carter, Jeffery D.
Mayfield, Wesley S.
Otis, Matthew R.
Fowler, Catherine R.
Suzuki, Tomoki
Hirota, Masao
Ishikawa, Yuichi
Schneider, Daniel J.
Janjic, Nebojsa
Pharmacokinetic Properties of DNA Aptamers with Base Modifications
title Pharmacokinetic Properties of DNA Aptamers with Base Modifications
title_full Pharmacokinetic Properties of DNA Aptamers with Base Modifications
title_fullStr Pharmacokinetic Properties of DNA Aptamers with Base Modifications
title_full_unstemmed Pharmacokinetic Properties of DNA Aptamers with Base Modifications
title_short Pharmacokinetic Properties of DNA Aptamers with Base Modifications
title_sort pharmacokinetic properties of dna aptamers with base modifications
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706628/
https://www.ncbi.nlm.nih.gov/pubmed/28961063
http://dx.doi.org/10.1089/nat.2017.0683
work_keys_str_mv AT guptashashi pharmacokineticpropertiesofdnaaptamerswithbasemodifications
AT droletdanielw pharmacokineticpropertiesofdnaaptamerswithbasemodifications
AT wolkstevenk pharmacokineticpropertiesofdnaaptamerswithbasemodifications
AT waughsheelam pharmacokineticpropertiesofdnaaptamerswithbasemodifications
AT rohloffjohnc pharmacokineticpropertiesofdnaaptamerswithbasemodifications
AT carterjefferyd pharmacokineticpropertiesofdnaaptamerswithbasemodifications
AT mayfieldwesleys pharmacokineticpropertiesofdnaaptamerswithbasemodifications
AT otismatthewr pharmacokineticpropertiesofdnaaptamerswithbasemodifications
AT fowlercatheriner pharmacokineticpropertiesofdnaaptamerswithbasemodifications
AT suzukitomoki pharmacokineticpropertiesofdnaaptamerswithbasemodifications
AT hirotamasao pharmacokineticpropertiesofdnaaptamerswithbasemodifications
AT ishikawayuichi pharmacokineticpropertiesofdnaaptamerswithbasemodifications
AT schneiderdanielj pharmacokineticpropertiesofdnaaptamerswithbasemodifications
AT janjicnebojsa pharmacokineticpropertiesofdnaaptamerswithbasemodifications